Second-generation long-acting injectable antipsychotics in clinical practice

Petrova N.N.; Grigorieva E.V.

doi:https://doi.org/10.17116/jnevro2022122021115

Close metadata

Recommended articles:

The relationship between inflammatory markers, fatigue, and effort-based decision-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91

The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48

A role of transcription factors in pathogenic processes associated with schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54

Metabolic syndrome and antipsychotic therapy of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170

Neuronal models based on olfactory epithelial cells in the study of the pathogenesis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):20-25

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34

Clinical and immunological relationships in patients with early schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

Analysis of cognitive status in patients with different nosologies and clinical variants of very late manifesting schizophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93

Abstract:

On the example of 5 clinical cases of paranoid schizophrenia at different stages of the development of the disease, the therapeutic tactics of using drugs from the group of second-generation injectable prolong antipsychotics to solve problems that arise during anti-relapse therapy are shown. The research data substantiating these approaches are presented. Various combination therapy options are discussed, including at the stage of drug replacement and the appointment of a second-generation long-acting injectable antipsychotic.

Keywords:

schizophrenia

anti-relapse therapy

second-generation long-acting injectable antipsychotics

clinical practice

Authors:

Petrova N.N.

Saint-Petersburg State University

ORCID: 0000-0003-4096-6208

Grigorieva E.V.

Evdokimov Moscow State University of Medicine and Dentistry

Received:

15.11.2021

Accepted:

19.01.2022

Close metadata

References:

Mathews M, Gopal S, Singh A, et al. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies. Neuropsychiatr Dis Treat. 2020;16:1533-1542. https://doi.org/10.2147/NDT.S221242
Stahl SM. Stahl’s Essential Psychopharmacology: Case studies. Vol. 2. Cambridge university press, 2015.
Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients with Schizophrenia. JAMA Psychiatry. 2017;74:686-693.
Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274-280. Epub 2017 Dec 21. https://doi.org/10.1016/j.schres.2017.12.010
Si T, Li N, Lu H, et al. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. J of Psychopharmacology (Oxford, England). 2018;32(6):691-701. https://doi.org/10.1177/0269881118772449
Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198-219.
Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1-24.
Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl. 2009;52:37-42.
Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry Suppl. 2009;52:1-4.
Skodlar B, Tomori M, Parnas J. Subjective experience and suicidal ideation in schizophrenia. Compr Psychiatry. 2008;4:482-488.
Barret EA, Mork E, Færden A, et al. The development of insight and its relationship with suicidality over one year follow-up in patients with first episode psychosis. Schizophr Res. 2015;162:97-102.
Petrova NN, Vishnevskaya OA. Clinical features of depression in remission of paranoid schizophrenia. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2013;11:34-41. (In Russ.).
Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2):127-135. https://doi.org/10.1177/026988110101500209
Ventriglio A, Gentile A, Bonfitto I, et al. Suicidal behavior in the onset of schizophrenia. Suicidology. 2017;8(2):20-28. (In Russ).
Pompili M, Orsolini L, Lamis DA, et al. Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role? CNS Neurol Disord Drug Targets. 2017;16(4):454-462. https://doi.org/10.2174/1871527316666170223163629
Tiihonen J, Walhbeck K, Lonnqvist J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after fi rst hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J. 2006;333:224-229.
Johnson DA, Pasterski G, Ludlow JM, et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983;67:339-352.
Möller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology. 2005;20(3):121-130.
Citrome L. Paliperidone palmitate: review of the efficacy, safety, and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010;64:216-239.
Martinuzzi E, Barbosa S, Daoudlarian D, et al. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Translational Psychiatry. 2019;9:20. https://doi.org/10.1038/s41398-018-0366-5
https://doi.org/10.33978/2307-3586-2020-16-4-36-38 Murmantsev KV, Khasanova DT. A modern view on the use of antipsychotic drugs in the practice of a hospital doctor. Effective pharmacotherapy. Neurology and psychiatry. 2020;16(4):36-38. (In Russ.).
Karson C, Duffy RA, Eramo A. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:57-67. eCollection 2016. https://doi.org/10.2147/NDT.S96392
Chumakov EM, Petrova NN, Limankin OV. Characteristics of the response to treatment in outpatients with the first episode of schizophrenia spectrum disorders. Vestnik of Saint Petersburg University. Medicine. 2019;14:3:216-225.
Petrova NN, Tsyrenova KA. Evaluation of adherence to antipsychotic therapy in patients with the first episode of schizophrenia. Modern Therapy of Mental Disorders. 2019;3:12-17. (In Russ.). https://doi.org/10.21265/PSYPH.2019.49.35972
Caseiro O, Pérez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46(8):1099-1105.
Emsley R, Chiliza B, Asmal L, et al. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv. Psychiatry. 2013;7(3):247-254.
Emsley R, Hargarter L, Bergmans P. Once-monthly paliperidone palmitate in early stage schizophrenia — a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia. Neuropsychiatr Dis Treat. 2017;13:2261-2269.
Nasrallah HA, Gopal S, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacol. 2010;35(10):2072-2082.
Patel C, Emond B, Lafeuille M-H, et al. Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. Drugs Real World Outcomes. 2020;7(1):19-29. https://doi.org/10.1007/s40801-019-00172-9
Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340. https://doi.org/10.1186/1471-244X-13-340
Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: dosing and switching strategies for long-acting risperidone. J Clin Psychiatry. 2003;64(suppl 16):41-46.
Keith SJ, Kane JM, Turner M, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry. 2004;65(1):120-131.
Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149-160. https://doi.org/10.1002/wps.20516
Porcelli S, Bianchini O, De GG, et al. Clinical factors related to schizophrenia relapse. Int J Psychiatry Clin Pract. 2016;20(2):54-69.
Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1-02):9-62. Epub 2017 Sep 14. https://doi.org/10.1055/s-0043-116492
Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13(7):767-783.
Janssen Pharmaceuticals Inc. Invega Trinza (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Titusville, NJ: Janssen Pharmaceuticals Inc.; March 2018.
Janssen Pharmaceuticals Inc. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Titusville, NJ: Janssen Pharmaceuticals Inc.; March 2018.
Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017;74(7):675-684.
Galling B, Roldan A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, metaanalysis and meta-regression analysis. World Psychiatry. 2017;16(1):77-89.
Correll CU, Sliwa JK, Najarian DM, Saklad SR. Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. CNS Spectr. 2019;24(4):354-370. https://doi.org/10.1017/S1092852918001098
Morris MT, Tarpada SP. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety. Psychopharmacol Bull. 2017;47(2):42-52. PMCID: PMC5472171.
Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830-839. https://doi.org/10.1001/jamapsychiatry.2015.0241
Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. International Journal of Neuropsychopharmacology. 2016;19(7):pyw018. Print 2016 Jul. https://doi.org/10.1093/ijnp/pyw018
Arteaga Duarte CH, Fakra E, Van Gils C, Guillon P. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study. Encephale. 2019;45(6):459-467. Epub 2019 Sep 18. https://doi.org/10.1016/j.encep.2019.03.001